Overview
Current NAV
14.0970
As on 30-Dec-2025
Fund Size
480.085 Cr
Managed by Ashish Agrawal
Expense Ratio
0.66%
Latest reported
Exit Load Rules
0
Conditions apply
Scheme Snapshot
This growth scheme operates in the equity small cap category with a risk profile of Very High Risk. Inception date 06-Feb-2024. Use the navigation above to explore performance, risk, portfolio holdings, analysis & exit load structure.
Data shown is for informational purposes only and may be delayed.
Returns
Green = Positive, Red = Negative| Period | Absolute % | CAGR % | Category % | Index % |
|---|---|---|---|---|
| 1D | -0.78 | — | — | — |
| 1W | -1.78 | — | — | — |
| 1M | -3.85 | — | — | — |
| 3M | 1.38 | — | 1.47 | — |
| 6M | 2.50 | — | 0.20 | — |
| 1Y | 2.79 | — | -2.14 | — |
| 3Y | — | — | 22.11 | — |
| 5Y | — | — | 14.61 | — |
| 10Y | — | — | — | — |
Top Holdings
Portfolio Allocation (Top 8+)
Company
Nature
Sector
% of Corpus
Sun Pharmaceutical Industries Ltd.
EQ
Healthcare
8.31
JB Chemicals & Pharmaceuticals Ltd.
EQ
Healthcare
7.29
Max Healthcare Institute Ltd.
EQ
Healthcare
6.81
Fortis Healthcare Ltd.
EQ
Healthcare
5.53
Laurus Labs Ltd.
EQ
Healthcare
4.94
Cipla Ltd.
EQ
Healthcare
3.80
Lupin Ltd.
EQ
Healthcare
3.58
Divi's Laboratories Ltd.
EQ
Healthcare
3.33
Sun Pharmaceutical Industries Ltd.
EQ
Healthcare
3.18
Neuland Laboratories Ltd.
EQ
Healthcare
3.09
Alkem Laboratories Ltd.
EQ
Healthcare
2.89
Sai Life Sciences Ltd.
EQ
Healthcare
2.61
Analysis Highlights
PROS
Lower expense ratio: 0.66%
PROS
1Y annualised returns higher than category average by 4.93%